Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with mXELIRI in advanced colorectal cancer
NCT05035914Phase 2Unknown
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in colorectal cancer (CRC), sponsored by Guangzhou University of Chinese Medicine. Status: unknown.
02
Drugs
anlotinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05035914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035914.